Scientists suggest understanding ecDNA’s role in pancreatic cancer could potentially guide future strategies for making ...

The team found that some pancreatic cancer cells gain a major survival edge by carrying copies of critical cancer genes—such ...

Pancreatic cancer’s deadly resilience may be tied to extrachromosomal DNA, which allows tumor cells to rapidly adapt to ...

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common ...

Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

This MYC overload is a factor in up to 75 percent of all human cancer cases, and the protein’s peculiarly chaotic structure has so far stymied medicine’s attempts to control it. MYC is “basically a ...

Linnaeus Therapeutics, Inc. ("Linnaeus"), a privately held biopharmaceutical company focused on the development and ...

Pancreatic cancer's adaptability and resistance to therapy are partly driven by extrachromosomal DNA (ecDNA), which carries critical cancer genes like MYC outside chromosomes.